梅花生物(600873) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was RMB 6,950,072,385.57, representing a year-on-year increase of 3.54%[4] - The net profit attributable to shareholders for Q1 2023 was RMB 800,793,127.47, a decrease of 30.89% compared to the same period last year, primarily due to a decline in gross margin from 26.24% to 19.84%[6] - Basic and diluted earnings per share for Q1 2023 were both RMB 0.26, reflecting a decrease of 29.73% year-on-year[4] - Total revenue for Q1 2023 reached RMB 6,950,072,385.57, an increase of 3.54% compared to RMB 6,712,290,632.48 in Q1 2022[16] - Operating profit for Q1 2023 is approximately ¥945.13 million, down 30.5% from ¥1.36 billion in the same period last year[17] - The net profit for Q1 2023 is approximately ¥800.79 million, a decrease of 30.9% compared to ¥1.16 billion in Q1 2022[17] - Earnings per share for Q1 2023 is ¥0.26, down from ¥0.37 in Q1 2022[17] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 54.20% to RMB 333,494,806.92, mainly due to increased raw material purchases[6] - Cash flow from operating activities for Q1 2023 is approximately ¥333.49 million, a decrease of 54.3% compared to ¥728.21 million in Q1 2022[18] - Cash flow from investing activities shows a net outflow of approximately ¥969.36 million in Q1 2023, slightly higher than the outflow of ¥965.77 million in Q1 2022[19] - Cash flow from financing activities results in a net outflow of approximately ¥217.90 million in Q1 2023, compared to a net outflow of ¥107.41 million in Q1 2022[19] - The company raised approximately ¥640 million in new borrowings in Q1 2023, significantly higher than ¥210 million in Q1 2022[19] - The company's cash and cash equivalents decreased to RMB 3,450,756,112.91 from RMB 4,333,600,657.71 year-over-year[13] - The total cash and cash equivalents at the end of Q1 2023 is approximately ¥3.27 billion, an increase from ¥2.90 billion at the end of Q1 2022[19] Assets and Liabilities - Total assets at the end of Q1 2023 were RMB 24,527,015,822.15, a slight increase of 0.15% from the end of the previous year[4] - The company's total assets amounted to RMB 24,527,015,822.15, slightly up from RMB 24,490,222,471.46 at the end of Q1 2022[15] - Total liabilities increased to RMB 11,599,502,934.70, compared to RMB 10,974,089,118.69 in Q1 2022, reflecting a growth of 5.69%[15] - The company's equity attributable to shareholders decreased to RMB 12,927,512,887.45 from RMB 13,516,133,352.77 in the previous year, a decline of 4.35%[15] - Short-term borrowings rose to RMB 1,324,462,695.04, an increase of 23.6% from RMB 1,070,498,635.74 in Q1 2022[15] - The total non-current liabilities decreased to RMB 3,916,073,176.45 from RMB 4,301,661,573.36, a reduction of 8.93%[15] Shareholder Information - The top shareholder, Meng Qingshan, holds 28.07% of the shares, with a total of 854,103,033 shares[7] - The company completed a share buyback of 99,039,345 shares, accounting for 3.26% of the total share capital at that time, with an average repurchase price of RMB 10.09 per share[11] - The company has initiated a new employee stock ownership plan, purchasing 28,260,800 shares for a total of RMB 295,296,438, representing 0.93% of the total share capital[11] - The company plans to continue implementing share buybacks in accordance with regulatory requirements[11] Strategic Focus and Growth - The increase in operating revenue was mainly driven by growth in sales of flavoring agents and xanthan gum products[6] - The company’s strategic focus includes enhancing its market position through potential mergers and acquisitions, although specific targets were not disclosed[11] - Research and development expenses increased to RMB 70,825,927.68, a rise of 19.93% from RMB 59,037,845.21 in the same period last year[16]